|Application ||WB, IHC-P, E|
|Other Accession||AAM97540, 25989575|
|Calculated MW||124674 Da|
|Application Notes||PIKE antibody can be used for detection of PIKE by Western blot at 0.5 to 2 µg/mL. Antibody can also be used for immunohistochemistry starting at 10 µg/mL.|
|Other Names||PIKE Antibody: PIKE, GGAP2, CENTG1, KIAA0167, Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 2, Centaurin-gamma-1, AGAP-2, ArfGAP with GTPase domain, ankyrin repeat and PH domain 2|
|Target/Specificity||AGAP2; Anti-PIKE will detect both PIKE-L and PIKE-A isoforms.|
|Reconstitution & Storage||PIKE antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||PIKE Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||GTPase-activating protein (GAP) for ARF1 and ARF5, which also shows strong GTPase activity. Isoform 1 participates in the prevention of neuronal apoptosis by enhancing PI3 kinase activity. It aids the coupling of metabotropic glutamate receptor 1 (GRM1) to cytoplasmic PI3 kinase by interacting with Homer scaffolding proteins, and also seems to mediate anti-apoptotic effects of NGF by activating nuclear PI3 kinase. Isoform 2 does not stimulate PI3 kinase but may protect cells from apoptosis by stimulating Akt. It also regulates the adapter protein 1 (AP-1)-dependent trafficking of proteins in the endosomal system. It seems to be oncogenic. It is overexpressed in cancer cells, prevents apoptosis and promotes cancer cell invasion.|
|Cellular Location||Isoform 1: Cytoplasm. Nucleus.|
|Tissue Location||Isoform 1 is brain-specific. Isoform 2 is ubiquitously expressed, with highest levels in brain and heart|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PIKE Antibody: Phosphoinositide 3 kinase enhancer (PIKE) is a recently identified nuclear GTPase that interacts with nuclear phosphoinositide 3-kinase (PI3 kinase) to stimulate its lipid kinase activity. PIKE exists in multiple isoforms; a shorter C-terminal isoform (PIKE-A) has also been identified as centaurin gamma 1. The longest isoform (PIKE-L) has been shown to bind to the adaptor protein Homer and thereby link to metabotropic glutamate receptors, leading to activation of PI3 kinase activity and prevention of neuronal apoptosis. Overexpression of PIKE-A enhances Akt activity and promotes cancer cell invasion, whereas decreased expression of PIKE-A via dominant negative expression of PIKE-A or PIKE-A knockdown inhibits these processes. In many human cancers, expression of PIKE-A is enhanced, leading to increased Akt activity and preventing apoptosis.
Ye K, Hurt KJ, Wu FY, et al. Pike. A nuclear gtpase that enhances PI3kinase activity and is regulated by protein 4.1N. Cell 2000; 103:919-30.
Jackson TR, Kearns BG, and Thiebert AB. Cytohesins and centaurins: mediators of PI3-kinase-regulated Arf signaling. Trends Biochem. Sci. 2000; 25:489-95.
Rong R, Ahn JY, Huang H, et al. PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis. Nat. Neurosci. 2003; 6:1153-61.
Ahn J-Y, Rong R, Kroll TG, et al. PIKE (Phosphotidylinositol 3-kinase enhancer)-A GTPase stimulates Akt activity and mediates cellular invasion. J. Biol. Chem. 2004; 279:16441-51.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.